MA-BIAL/LYSOSOMAL
1.10.2020 13:02:10 CEST | Business Wire | Press release
BIAL, a pharmaceutical company based in Portugal with locations across Europe and dedicated to R&D in CNS diseases, announced today that it has established a new affiliate in the United States of America, BIAL Biotech Investments Inc. (BIAL Biotech). This new research center focused on genetically-defined Parkinson’s disease is based in Cambridge, Massachusetts, a prominent biotech hub in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005323/en/
Simultaneously, BIAL announced that it has acquired worldwide rights of LTI-291 and all the Parkinson’s disease research programs of Lysosomal Therapeutics Inc. (LTI) and taken on the entire R&D team.
António Portela, executive president of BIAL, reveals: “Our entry into the US with the creation of BIAL Biotech and the acquisition of the promising programs from LTI, is a decisive step towards the fulfilment of our mission to contribute to improving the quality of life of people worldwide. The development of this new research center in the US, is a landmark of enormous relevance for us. We are investing in science and research, through our direct presence in one of the most important research hubs in the world and in one of the most promising areas of medicine. ”
This acquisition not only provides the company with a pipeline of new product candidates in Parkinson’s disease but also an experienced R&D team, led by Peter Lansbury, professor of neurology at Harvard Medical School and a recognized thought leader in the field of neurodegenerative diseases.
With this acquisition, BIAL is expanding its pipeline, namely with the integration of new compounds in neurodegeneration already in clinical development, specifically for Parkinson's disease, where the pharmaceutical company already has a significant market position.
The executive president of BIAL also points out: “The compounds we’ve acquired are based on genetics, a new field of research for us. The lead asset, which now has the code name 'BIA 28-6156/LTI-291', has an innovative mechanism of action and presents the potential of being a first disease-modifying therapy for a genetic subset of Parkinson’s disease. It has successfully completed a Phase I trial program and should be ready to start Phase II studies in 2021. We´re progressing from symptomatic treatment to an intervention in the mechanisms of the disease, which is very exciting for BIAL. ”
“We are happy to be part of BIAL and take the lead on the growth story in the US,” says Kees Been, former CEO of LTI and now CEO of BIAL Biotech. "With the commitment and resources of BIAL we will be able to accelerate our novel clinical and research programs as targeted and personalized treatment approaches for genetically-defined PD patients.”
“On behalf of the LTI shareholders, I want to express our enthusiastic endorsement of BIAL as a good home for the programs of LTI, ” said Clay B. Thorp, General Partner, Hatteras Venture Partners. “This deal is a perfect fit and we have great confidence that the team, with the resources and commitment of BIAL, will advance LTI-291 and the other compounds rapidly to patients to treat this debilitating form of Parkinson’s disease. ”
BIA 28-6156 / LTI-291 is a drug compound aimed at treating patients with GBA-Associated Parkinson’s diseases (GBA-PD) caused by an underlying mutation in the GBA1 gene. This genetic mutation affects approximately 10% to 15% of Parkinson’s disease patients (100,000-150,000 patients in the US) and is a validated risk factor that generally leads to an earlier age of disease onset and more rapid disease progression.
In addition to an upfront payment, the total value of the deal could reach up to 130 million dollars, based on attainment of a series of milestone payments as the assets progress through the clinic and into the market. Other financial terms will not be disclosed.
About BIAL Biotech
BIAL Biotech is a Center of Excellence for the development of genetically-defined Parkinson’s disease therapeutics located in the heart of the Boston biotech cluster. BIAL Biotech is a wholly owned subsidiary of BIAL, a pharmaceutical company based in Portugal with locations across Europe.
About BIAL
Founded in 1924, BIAL's mission is to research, develop and provide therapeutic solutions within the area of health. In the last decades, BIAL has focused strategically on quality, innovation and internationalisation. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide.
For more information on BIAL: www.bial.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005323/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
57% of Brands Can't Prove ROI on Sports Fan Engagement Despite Rising Investment8.9.2026 11:30:00 CEST | Press release
Infobip’s new global research reveals a gap between higher spend and measurable ROI Research commissioned by Infobip, the global AI-first cloud communications platform celebrating 20 years, shows brands are significantly increasing investment in sports fan engagement even as many struggle to prove business impact. The global study of 500 marketing and digital leaders across industries, including retail, financial services, telecoms, travel, and food & beverage in 11 markets found that brands currently allocate an average of 13% of annual marketing budgets to sports-related activations, and nearly 73% expect investment to increase over the next 12 months. Yet while live sports moments generate the highest levels of fan engagement, nearly half (47%) of organizations admit they struggle to deliver real-time engagement during live events, and more than half (57%) say it is difficult to prove the ROI of their sports marketing investments. Ben Lewis, VP Marketing and Growth at Infobip, said:
Red Sea Global Unveils Nammos Resort AMAALA, Introducing Nammos’ First Resort Hotel Globally8.9.2026 10:59:00 CEST | Press release
The internationally renowned lifestyle and hospitality brand makes its debut in the Middle East Red Sea Global (RSG), the regenerative tourism developer, today announced the opening of Nammos Resort AMAALA, marking the launch of Nammos’ first resort hotel globally and a significant addition to AMAALA’s growing lifestyle and hospitality offering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908621917/en/ A marvellous view of the night sky from inside the resort hotel Set along the shores of Triple Bay with sweeping views across the Red Sea and Dumega Bay and designed around Nammos’ philosophy of Endless Joy, Nammos Resort AMAALA introduces the brand’s distinctive blend of Mediterranean sophistication and vibrant social energy to one of the world’s most comprehensive wellness destinations. “Nammos Resort AMAALA strengthens the diversity of experiences available across the destination bringing the unmistakable energy and s
Icon Solutions and MongoDB Benchmark Shows IPF Processing 6,000 Payments per Second with Zero Data Loss Under Failure8.9.2026 10:54:00 CEST | Press release
Joint benchmark on MongoDB Atlas demonstrates near-linear scalability, sub-second end-to-end latency and recovery from application and database node failures without losing a single transaction. Icon Solutions and MongoDB today published the results of a joint benchmark showing that the Icon Payments Framework (IPF), running on MongoDB Atlas, processed 6,000 end-to-end payment transactions per second (around 430,000 database operations per second) with a mean end-to-end latency of 0.51 seconds, and recovered from both application and database node failures with zero data loss. Account-to-account payment volumes are moving rapidly onto instant rails. Traffic is migrating from net-settlement schemes to instant schemes, and direct debit volumes are expected to partially move to request-to-pay with settlement through instant schemes. For banks, that means sharper traffic peaks, a growing share of payments bound to scheme SLAs of a few seconds, and no tolerance for downtime. Sustaining seve
NTT DATA Deploys AI-Powered Platform to Elevate Global Infrastructure Operations8.9.2026 10:00:00 CEST | Press release
Real‑time monitoring and predictive analytics improve stability and efficiency. Scope includes AI-enabled operations for IT and cloud infrastructure, SAP Basis and network operations worldwide. NTT DATA, a global leader in AI, digital business and technology services, is expanding the deployment of its AI-powered infrastructure operations platform to support complex global enterprise environments. The platform combines real time monitoring, predictive analytics and intelligent automation to enhance operational resilience, efficiency and visibility. Deployment of these capabilities includes support for one of the largest commercial vehicle manufacturers. “Our AI-powered platform significantly increases transparency and automation, providing the foundation for greater stability, faster response times and a future-ready IT architecture,” said Abhijit Dubey, CEO and Chief AI Officer, NTT DATA, Inc. “Our work with Daimler Truck is one example of how we canoperate global IT infrastructures s
Wolters Kluwer launches Libra Academy across Europe to help legal professionals realize the full value of legal AI8.9.2026 09:01:00 CEST | Press release
Developed by lawyers for lawyers, Libra Academy brings together learning resources, use cases and a European user community to accelerate AI adoption and customer success Wolters KluwerLegal & Regulatory today announced the launch of Libra Academy, a new learning and enablement platform around the company’s legal AI workspace Libra by Wolters Kluwer, designed to help legal professionals confidently integrate AI into their daily work. As legal teams increasingly look to move beyond experimentation and achieve measurable productivity gains, they face a new challenge: keeping pace with an AI landscape that evolves faster than traditional training can follow. New features, models, and use cases emerge continuously, making it difficult for busy legal professionals to stay current while managing the demands of their daily work. Libra Academy was created to close this gap. Built directly into the Libra experience, it provides continuous learning that evolves alongside the platform, helping cu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom